Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells

Cell Death and Differentiation

Volumn 8, Issue 5, 2001, Pages 457-469

  Tentori, L ^a   Portarena, I ^a   Bonmassar, E ^a,b   Graziani, G ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

Chemotherapy; DNA repair; Drug resistance; Methylating agents

Indexed keywords

DNA; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P53; TEMOZOLOMIDE; VIRUS VECTOR;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASE MISPAIRING; CELL GROWTH; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DRUG EXPOSURE; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR CELL LINE; TUMOR RESISTANCE;

ADENOVIRIDAE; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BASE PAIR MISMATCH; BLOTTING, WESTERN; BROMODEOXYURIDINE; CELL DIVISION; DACARBAZINE; DNA REPAIR; DNA REPLICATION; ENZYME INHIBITORS; FLUOROURACIL; GENE DELETION; GENETIC VECTORS; HUMANS; JURKAT CELLS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN TRANSPORT; QUINAZOLINES; THIOPHENES; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035009692     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4400832     Document Type: Article

References (58)

1. Cell cycle control and cancer
2. p53, cell cycle control and apoptosis: Implications for cancer
3. p53, the cellular gate-keeper for growth and division
4. p53 status and the efficacy of cancer therapy in vivo
5. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck
6. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis
7. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus
8. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein
9. p53 tumor suppressor gene therapy for cancer
10. The p53 tumour suppressor gene
11. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas
12. Microsatellite instability and p53 mutations in therapy related leukemia suggest a mutator phenotype
13. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia
14. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
15. Mechanisms of relapse in acute leukemia: Involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia
16. Eukaryotic mismatch repair: An update
17. The role of DNA mismatch repair in drug resistance
18. Involvement of the mismatch repair system in temozolomide-induced apoptosis
19. Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase
20. Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds
21. Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials
22. 6-alkylguanine-DNA alkkyltransferase activity
23. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents
24. Life without DNA repair
25. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene
26. Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells
27. Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent
28. Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo
29. Adenovirus-mediated wild-type p53 gene transfer and overexpression induces apoptosis of human glioma cells independent of endogenous p53 status
30. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis
31. In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug
32. Differential efficacy of adenoviral mediated gene transfer into cells from hematological cell lines and fresh hematological malignancies
33. WAF1, a potential mediator of p53 tumor suppression
34. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis
35. Cytotoxic effects of dacarbazine in patients with acute myelogenous leukemia: A pilot study
36. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma
37. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrycytoma at first relapse: Temodal Brain Tumor Group
38. Cancer Research Campaign phase II trial of temozolomode in metastatic melanoma
39. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
40. Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule
41. Acute overexpression of WT p53 facilitates anticancer drug-induced death of cancer and normal cells
42. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells
43. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian prostate and breast cancer
44. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers
45. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
46. A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours
47. p53-mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy
48. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair
49. Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival
50. Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation
51. A DNA-dependent protein kinase inhibitor (OK-1035) suppresses p21 expression in HCT116 cells containing wild-type p53 induced by adriamycin
52. Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T-cell leukemic line tolerant to methylating agents
53. Polymerase delta variants in RER colorectal tumors
54. Mutation of a mutL homologue in hereditary colon cancer
55. Hypermutability and mismatch repair deficiency in RER+ tumor cells
56. p53 mutations in Raji cells: Characterization and localization relative to other Burkitt's lymphomas
57. 1 phase arrest and p53 function in human tumor cells
58. Potentiation of temozolomide-induced cytotoxicity: A comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors